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Monoclonal antibody recognition of cholesterol monohydrate 
crystal faces 
Daniele Perl-Treves, Naama Kessler, David lzhaky and Lia Addadi 
Background: The immune system can elicit antibodies against a wide variety of 
antigens. We have proposed that crystal surfaces may also operate as antigens, 
binding specific antibodies. Here we exploit the crystal surfaces of cholesterol 
monohydrate to investigate antibody-surface recognition at the molecular level. 
Results: Four monoclonal antibodies were selected. Two specifically interact 
with cholesterol monohydrate crystals, and one with 1 ,Cdinitrobenzene crystals. 
The fourth interacts nonselectively with various solid substrates. The relative 
reactivities of the four antibodies to the different surfaces of cholesterol 
monohydrate and to other surfaces were compared. The nonspecific antibody 
adsorbs mainly at imperfections. Of the two specific antibodies, one shows a 
clear preference for one set of faces, relative to others, the second adsorbs 
selectively at one face of cholesterol monohydrate crystals. 
Conclusions: Monoclonal antibodies can be selected that specifically bind to 
the crystal surfaces of cholesterol monohydrate. The binding sites of such 
antibodies appear to recognize a number of molecular moieties, exposed at the 
surface in a specific structural organization. Different antibodies recognize 
different structural organizations with varying degrees of selectivity. 
Antibody-crystal surface interactions may serve as convenient models for studies 
aimed at an understanding of the molecular bases of antibody recognition. 
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Introduction 
The recognition of a protein antigen by an antibody 
involves interactions between the exposed surfaces of the 
two molecules. Determination of the molecular structure 
of such antibody-antigen complexes by X-ray crystallo- 
graphy has shown that the topography of the contact area is 
often quite flat, and that the surface conformation of the 
antigen does not change substantially upon binding [ 1,2]. 
Even though the number of structures of antibody-antigen 
complexes known is constantly increasing, it is still impos- 
sible to systematically analyze and understand the basic 
rules of molecular recognition underlying the specific 
interactions between the antibody complementarity- 
determining region and the protein antigen. A protein 
surface is highly heterogeneous both in geometry and in 
chemical nature. Moreover, there are many epitopes 
available on the exposed surface of the protein, and the 
selection is not easily predictable. To study the general 
rules of molecular recognition, it would appear convenient 
to study a series of antibody-antigen complexes where the 
antigen is well determined and its variability is under 
control. Crystal surfaces may answer these requirements. 
The structures of molecular crystals are easily determined 
and can be defined at the atomic level. They are 
characterized by highly ordered, repetitive motifs of 
molecules. The molecular components of the crystal will 
be exposed on the different faces of the crystal in different 
orientations, exhibiting different chemical moieties in a 
known pattern. 
It appears that both the organization of the antigen 
and the spatial orientation of its epitopes are indeed 
important for antibody recognition. For example, an 
anti-virus antibody showed a stronger response when 
the glycoprotein antigen on the outer membrane was 
presented in a highly organized repetitive form [3]. 
Similarly, an anti-phospholipid antibody was shown to 
interact with its antigen only when the latter was orga- 
nized in the hexagonal phase, and not in the lamellar 
phase [4]. 
We have proposed that, in principle, the flat and rigid 
surfaces of molecular crystals can act as antigens, eliciting 
the production of specific antibodies [5,6]. Antibodies 
against nonprotein antigens containing repetitive patterns 
have been characterized in other systems such as 
polysaccharides [7], synthetic polymers with repeating 
arrays of identical units [8] and viruses [3]. These 
repetitive antigens generally elicit a ‘T-cell independent’ 
immune response, in which the response to the antigen by 
the antibody-producing B cell is direct, and does not 
require presentation of the antigen to T cells via MHC 
molecules [9]. Such a mechanism may be active in the 
production of antibodies against crystals. 
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In the case of a crystal surface antigen, each epitope 
would be constituted by an array of molecules over an 
area identified as the antibody-binding site. In pro- 
tein-antibody complexes the area that an antibody covers 
on a protein is typically -600-900 A2 [l,lO]. This is the 
area covered by an array of 7-25 molecules with a cross 
section of 5 x 5-10 x 10 A each. If this array can bind 
antibodies with high affinity, then the antibody must be 
recognizing a repetitive series of molecular moieties in 
the correct arrangement. On each crystal face, the recog 
nition sites would thus have well defined chemical 
characteristics, which differ one from the other, and from 
those of the component molecule. We note that such 
specific interactions between functionalized domains on 
protein surfaces and a number of matching moieties on 
specific crystal faces have been observed with proteins 
other than immunoglobulins in different systems where 
crystals are exposed to biological environments [l l-131, 
We have shown that the immune system can respond to 
the introduction of a foreign crystal in the organism by 
producing specific antibodies [5,14]. Polyclonal IgG raised 
against three different crystals (monosodium urate mono- 
hydrate, magnesium urate octahydrate and allopurinol) 
each catalyzed the nucleation of the respective crystals in 
oitro. Similarly, IgG isolated from the joint fluid of 
patients suffering from gout, a disease associated with the 
presence of monosodium urate monohydrate crystals in 
joints, selectively catalyzed the nucleation of monosodium 
urate monohydrate [S]. This was explained by assuming 
that some antibodies developed against the crystal faces 
bear in their binding site a structured imprint of a number 
of molecular moieties exposed on the crystal surface, 
These antibodies may thus act as stabilizing templates in 
a new crystallization event. Although the component 
molecules of the three crystals are quite similar, little or no 
cross-nucleating effect was observed, indicating a high 
level of complementarity between the antibodies and the 
crystal surface structures [ 141. 
To further elucidate the antibody-crystal interactions at 
the molecular level and evaluate the level of specificity 
that can be reached in antibody-crystal interactions, 
monoclonal antibodies are required. Here we chose to raise 
and examine monoclonal antibodies against cholesterol 
monohydrate crystals. This choice was motivated by the 
fact that cholesterol, in the living organism, may aggregate 
or precipitate in pathological situations as crystals (gall 
stones, atherosclerosis). As the molecule is not charged, we 
predicted that nonspecific adsorption would be reduced, 
increasing the chance of obtaining specific antibodies. The 
crystal furthermore presents an interesting variety of 
surface structures, on which specificity can be tested at 
high molecular resolution. Finally, generation of mono- 
clonal antibodies against a different cholesterol-containing 
system, cholesterol-rich liposomes, has been described by 
Swartz et al. [ 151, providing a convenient closely related 
system for comparison. 
Three monoclonal antibodies that strongly interact with the 
surface of cholesterol crystals were selected and character- 
ized by various immunolabelling techniques. They present 
an interesting range of recognition levels, from nonspecific 
to highly specific, One of them was shown to interact 
selectively with a single crystal face of unique character. 
Rasults 
Choloatwol monohydnto crystal8 and rntlbody wloctlon 
Cholesterol monohydrate crystals were obtained from 
supersaturated cholesterol solutions of 20 % water in 
acetone. These crystals exhibit smooth {OOl} plate faces, 
as in the typical morphology [16], but faces from the {no/) 
and (OR4 families are also well developed. (Note: The 
notation {h,k,l) indicates the family of symmetry-related 
faces or planes, (h,k,l) indicates one member of the family, 
and [h,k,l] indicates the direction of the vector 
perpendicular to the plane.) The number and indices of 
these faces vary among crystals. The basic crystal 
morphology is presented in Fig. la. Cholesterol mono- 
hydrate crystallizes as bilayers, exposing along the {OOl} 
plane the hydrophobic tail of the molecule or the 
hydroxyls and lattice water molecules in alternate layers 
(Fig. lb,c). The {OOl} faces may thus have hydrophilic or 
hydrophobic character, depending on the environment to 
which they are exposed, In water, the hydroxyl-water 
layer is preferentially exposed, and the face consequently 
has a hydrophilic character. The {do/) and {Ok/) faces 
expose the cholesterol molecular backbone and have a 
more hydrophobic character. All the (/JO/) faces with /# 0, 
and {OR/) faces with /, R # 1 have molecular steps where 
the water molecules and the cholesterol hydroxyl groups 
are exposed. In contrast, the {loo} and (01 l} faces, which 
do not contain such steps, are completely hydrophobic. 
Two crystal types were used for immunization, cholesterol 
monohydrate and 1,4-dinitrobenzene (DNB). The latter 
molecule, when linked to a protein carrier, is a well-known 
immunogen. Crystals of DNB expose at their surfaces 
benzene and nitro groups in various arrangements, and are 
very different from cholesterol crystals. 
Following immunization with the two crystal types, 
monoclonal antibodies (MAbs) were selected on the basis 
of their relative affinity to the two crystals. The 
characterization of these hybridoma clone populations is 
reported elsewhere [17]. Four clones were analyzed here 
in depth. MAb 36Al and SUB1 interact strongly with 
cholesterol crystals, but not with DNB crystals. MAb 
122Bl interacts with 1,4-DNB crystals, but not with 
cholesterol crystals, and was used as a negative control. 
MAb 23C1, an antibody obtained from a mouse exposed 
to 1,3-DNB crystals, adsorbs strongly to both types of 
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The structure and morphology of cholesterol crystale. (I) Scanning Crystal structure of choleeterol monohydrate; (b) viewed in the DO01 
electron micrographs of cholesterol monohydrate crystals grown from direction or (c) viewed in the [01 01 direction [24]. The H atomic ..- - -. 
acetone/water, 80120. Inset: typical morphology of choleeterol 
monohydrate ctyetale grown under these conditions. (b) and (c): 
positions are not marked. C - l , 0 = o. The planes that are developed 
as stable faces are indicated, 
crystal surfaces, and is considered nonselective. A 
commercial monoclonal IgM antibody selected against 
cholesterol-rich liposomes (2C5-6) [14] was used as an 
additional control. MAb 36Al was obtained after immuni- 
zation with cholesterol monohydrate crystals, MAb 58Bl 
and 122Bl after immunization with 1,4-DNB crystals. All 
the MAbs selected were of IgM type. Interestingly, one of 
the cholesterol-binding antibodies originated from the 
population obtained after immunization with DNB 
crystals [17]. 
Blndlng of the antlbodles to solld substrates 
The selected monoclonal antibodies were first character- 
ized by enzyme-linked immunosorbent assay (ELISA), 
examining their binding to three types of solid surfaces: 
crystals of cholesterol monohydrate, crystals of 1,4-DNB, 
and the polystyrene surface of microtiter plates. The 
crystals were incubated with sequential dilutions of 
antibody in the presence of a blocking agent, 0.5 % bovine 
serum albumin (BSA). In the absence of blocking agent, 
higher binding was observed, presumably due to non- 
specific adsorption of the antibodies to the crystal surfaces. 
In a representative experiment with MAb 36A1, the optical 
density (OD) in the presence of BSA was 0.4, and in the 
absence of BSA was 0.7. The results of the ELISA are 
shown in Figure 2. The monoclonal antibody selected as 
cross-reactive, 23C1, indeed bound strongly to all three 
solid surfaces examined. In contrast, MAb 58Bl and 122Bl 
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Monoclonal antibody binding to solid substrates. Binding of monoclonal 
antibodies 36A1,56Bi, 23Cl and 12281 to: (a), (d) cholesterol 
monohydrate crystals; (b) 1,4-DNB crystals; (c) a polystyrene microtiter 
plate. The reactivity is measured in a solid-state ELISA (A = 402 nm). 
Each value represents the average of at least two reactions at the 
indicated dilution of hybridoma medium in (a), (b) and (c), and of ascites 
in (d). Note the differences in OD scale among the graphs. 
bound with high selectivity to cholesterol monohydrate 
and 1,4-DNB crystals, respectively. MAb 36Al bound 
weakly to the hydrophobic polystyrene surface but showed 
overall selectivity for cholesterol monohydrate. MAb ZCS-6 
did not bind to cholesterol monohydrate crystals under our 
experimental conditions. The selected hybridomas thus 
appear to be sensitive to the chemical and structural 
composition of the crystal surfaces. The concentrations of 
IgM in the different hybridoma media were similar (data 
not shown), except for MAb ES-6 where the medium 
contained a lower concentration of IgM. Ascitic fluid of 
2C.56 was therefore also examined (Fig. Zd). 
Antibody binding to noncrystalline cholesterol 
We next addressed the question of whether the 
monoclonal antibodies recognize the molecular compo- 
nents of the crystal, or a repetitive pattern of the 
component molecules on crystal faces. The first indica- 
tion of this is intrinsic to the experimental set up of 
the crystals. All experiments with crystals must be per- 
formed in cholesterol-saturated solutions to avoid crystal 
dissolution, as cholesterol has a low but significant 
solubility in 0.5 % BSA-enriched buffer. Binding to the 
crystal is thus always studied in competition with binding 
to molecular or BSA-associated cholesterol present in 
solution. To further test the reactivity of the antibodies to 
molecular cholesterol, BSA-cholesterol conjugates were 
prepared. Cholesterol molecules were attached to BSA 
through the hydroxyl group in position 3l3, through the 
Figure 3 
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BSA-cholesterol conjugates. 1 Cholesteryl hemisuccinate; 2 5cholenic 
acid-36-01; 3 5-cholesten-3f3-ol-7-(O-carboxymethyl)oxime. 
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hydrophobic tail in position 24, or in position 7 (Fig. 3), 
using two different synthetic procedures. On the average 
8 or 13 molecules of moiety 1, 5 or 4 molecules of moiety 
2 (in the two procedures) and 4 molecules of moiety 3 
were attached per BSA molecule respectively. Binding of 
the selected antibodies, including MAb ZCS-6, to the 
polysterene-adsorbed BSA conjugates, was then tested by 
ELISA. The antibodies bound to the cholesterol-BSA 
conjugates with the same affinity as to the carrier protein 
treated in the same way but without conjugation. There 
was thus no binding to the cholesterol moieties. 
Taking a different approach, cholesterol was adsorbed 
onto polystyrene microtiter plates, by drying ethanol 
solutions containing 0, 1 and 10 p,g of cholesterol per well 
respectively. The cholesterol molecules are presumably 
present on the plate in different aggregation states. Only a 
few microscopic crystals were observed with 1 pg of 
cholesterol per well, while significantly more crystals were 
present at 10 p,g cholesterol per well. Binding of mono- 
clonal antibodies to cholesterol attached to the plates was 
then examined (Fig. 4). MAb 58Bl did not recognize 
cholesterol deposited on the plate, whereas MAb 36Al 
bound slightly to preadsorbed cholesterol. The cross- 
reactive MAb 23Cl reacts strongly with cholesterol under 
the same conditions. MAb X5-6, raised against chol- 
esterol-rich liposomes, bound to cholesterol adsorbed on 
polystyrene plates, as reported [15]. However, the 
Figure 4 
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Binding of monoclonal antibodies to cholesterol adsorbed on tissue 
culture dishes. The amount of cholesterol per well was varied. l 
denotes 0 f.r,g, n 1 pg and A 10 )*g of cholesterol per well. Binding 
was measured by ELISA, X = 402 nm. Each value represents the 
average of two reactions with undiluted hybridoma medium, or with 
ascites diluted l/l 0. Ascites was used for 2C5-6 as the concentration 
of IgM in the corresponding hybridoma medium is relatively lower than 
in other hybridoma media. 
response was higher with 1 pg cholesterol deposited in 
the well than with 10 kg. These results, in conjunction 
with those obtained for adsorption onto the crystals, 
indicate that MAb XX-6 binds to some type of adsorbed 
cholesterol aggregates, but not to cholesterol crystals. 
lmmunolabelling experiments 
Each different face of cholesterol monohydrate crystals 
exposes a surface with a distinct chemical and structural 
character. An antibody that recognizes a defined molecular 
pattern is thus expected to interact differently with the 
various crystal faces. Determination of the distribution of 
antibodies on the different crystal faces would allow 
definition of the molecular patterns recognized. Exper- 
imentally, mapping of antibody on crystal surfaces was 
performed using immunofluorescence and immunogold 
labelling. Goat anti-mouse secondary antibodies labelled 
with rhodamine were used in immunofluorescence 
studies. The cholesterol crystals appeared under the light 
microscope either as parallelograms (when the (OOl} faces 
are viewed), or as polygons (when their {/lo/l or {Ok/) faces 
are viewed) (See Fig. la). We note that the (401) and (OR/l 
faces have a layered structure and contain imperfections. 
Crystal imperfections are high energy binding sites and 
constitute favored locations for nonspecific interactions. 
BSA was thus used in the binding assays as a blocking 
agent. In control experiments, crystals incubated with 
dansyl-labelled BSA exhibited fluorescence from all faces, 
especially from crystal imperfections, indicating that BSA 
indeed behaves as a nonspecific blocking agent (data not 
shown). Crystals incubated with MAb 23Cl in the 
presence of BSA exhibit a strong fluorescence, originating 
mainly from the imperfections on all crystal faces (Fig. 5a, 
b). In contrast, following incubation with MAb 36Al and 
58B1, the fluorescence uniformly emanated from the sides 
of the crystals that are lying on their (001) face (Fig. SC). 
This is not due to an optical artefact, as observation of the 
crystals lying on their side faces confirmed that 
homogeneous fluorescence indeed emanates from these 
faces (Fig. 5d). When monoclonal antibodies were 
omitted, the crystals were hardly fluorescent. This 
unambiguously demonstrates preferential binding of 
monoclonal antibodies 36Al and 58Bl to the {/zOl) or (Ok4 
faces. Many crystals were examined. In some of the 
crystals incubated with MAb 36A1, one of the faces 
exhibited a much stronger fluorescence than the other 
faces (Fig. Se). 
Under the light microscope, it is neither possible to 
distinguish whether crystals are viewed along the a* orb” 
axes, nor to assign the indexes of the faces viewed. At this 
stage we therefore could not ascertain whether the 
antibodies recognize particular faces of the {LOl) and (Ok/) 
families. This problem was solved by examining crystals 
labelled with 30 nm colloidal gold beads (coated with 
secondary antibodies) with a scanning electron 
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lmmunofluoreecence Iabetting of cholesterol crystals with antibodies. 
Bright field (bottom panel) and fluoreecence (upper panel) 
micrographe of oholeeterol monohydrate cry&ale, incubated with 
monoclonal antibodies and labelled with goat-anti-mouse F(ab), 
rhodamine-conjugated secondary antibodies. Magnification ie 160x. 
(e) View of the (001) face of a crystal incubated with MAb 23C1, (b) 
View of the (h01) or (Ok4 faces of a crystal incubated with MAb 23C1, 
(c) View of the (001) face of a crystal incubated with MAb 66Bl. 
Crystals incubated with 36A1 appear the same. (d) View of the (ho/) 
or (Ok/) aide faces, following incubation with MAb 66B1, (0) View of 
the (h01) or (Ok/) aide facee of cry&ale incubated with MAb 36Al I 
Note that the exposure times were not equal, and the fluorescence 
intensities are thus not comparable. 
microscope. In the scanning electron microscope, the 
crystal faces were exactly identified by measuring the 
dihedral angles they form with the easily identifiable 
(001) plate face (see Materials and methods). The 
concentration of gold beads on each face was then 
determined by counting the beads in a set of frames 
(three or four for each face) at a magnification of 20 000x. 
Three to six crystals were examined for each orientation 
({OOl}, {nod and {ORl)), for each antibody. Each value 
reported in Figure 6 thus represents the average count of 
at least nine frames. The frames were deliberately chosen 
in regions of the crystal surface presenting very few 
imperfections. It is still possible that the antibody may be 
associated with imperfections, such as kinks or steps, of a 
size lower than the resolution of the instrument. At a 
magnification of 20 000x, the resolution of visible steps is 
-10-20 nm. If the antibodies were concentrated along 
parallel steps, however, one would expect to observe rows 
of gold beads in the direction of the steps, even if the size 
of the step was smaller than the resolution of the 
instrument. No such alignments were seen, 
For all three monoclonal antibodies studied, the extent of 
gold labelling is lower on the {OOl} faces. The relative 
difference in label intensity was less pronounced with 
antibody 23Cl. This antibody appears also to give a lower 
response, relative to the other antibodies, than would be 
expected from the ELISA results. The counting of gold 
beads does not take into account gold beads concentrated at 
macroscopic imperfections, however, where immunofluor- 
escence showed that this antibody tends to concentrate. 
Macroscopic imperfections are not monitored, because frames 
containing them are not flat, making counting impossible. 
The overall response of monoclonal antibody 36Al was 
much stronger than that of 58B1, as already observed in 
the ELISA experiments. Comparison of the binding to 
lateral faces for antibody 58Bl shows that the average 
number of gold beads bound to the {/rOo faces is 2-3 times 
higher than on the {OR/) faces. No clear difference was, 
however, observed between the faces on the same side of 
the crystal. In contrast, observation of the {A00 faces of the 
crystals incubated with 36Al showed one particular face, 
(301) or (401), populated with an extremely high number 
of gold beads. This high order face is very close to the 
(100) face. The latter, (loo), forms an angle of 81” with the 
(001) face, the former two, (301) and (401), of 76” and 75”, 
respectively. The presence of {401} or (301) faces could 
only be ascertained thanks to crystals where both (100) 
and (401)/(301) faces were present. Since (401) and (301) 
faces are geometrically very close and have similar 
chemical characteristics, we cannot distinguish between 
them and will refer to them as (301) faces. Interestingly, 
the (100) and (301) faces behave very differently with 
respect to adsorption of antibody 36Al (Figs 6,7). 
Approximately twice as many gold beads are attached to 
the (301) face than to any other of the lateral crystal faces. 
I3011 faces are not always present, and the result is thus in 
agreement with the immunofluorescence studies where 
one face was occasionally, but not always, seen to 
fluoresce more strongly than the others. 
Dlscusslon 
In this study, we have shown that monoclonal antibodies 
can be selected that specifically recognize the surface of 
cholesterol monohydrate crystals. These antibodies do 
not seem to recognize the cholesterol molecule, but 
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Comparison of immunogold-labelling counts of MAb 23C1, 6881 and 
38A1, adsorbed on the different faces of choleeterol monohydrate 
cryetale. Grey, 23Cl; white, 6361; black, 38Al I Each value represents 
the average of counts performed in at least nine frames. 
rather defined molecular motifs exposed on some of the 
crystal faces. 
Cholesterol is a fundamental component of cell mem- 
branes, and the question of whether it can be immu- 
nogenic has attracted much interest over the years. The 
cholesterol molecule has generally been shown to be 
nonimmunogenic or poorly immunogenic [18]. In con- 
trast, cholesterol-rich liposomes (containing more than 
70 % cholesterol) where the cholesterol molecules are 
Figure 7 
presumably not present as isolated entities but in 
organized domains, can elicit the formation of specific 
antibodies [ 151. The monoclonal antibodies selected 
against such liposomes were shown to recognize choles- 
terol adsorbed on polystyrene plates as well. One of these 
antibodies, MAb 2C5-6, was tested in our system. Under 
the conditions of our experiment, MAb X5-6 did not 
recognize cholesterol monohydrate crystals. Its reactivity 
also decreased when a higher amount of cholesterol was 
deposited on the plate, although the higher amount 
resulted in a significant increase in the number of 
microscopic crystals formed. We therefore believe that 
MAb 2C5-6 recognizes a form of aggregated cholesterol 
that is present in the liposomes and in plate-adsorbed 
cholesterol, but not in the strictly defined and organized 
surfaces of cholesterol monohydrate crystals. In contrast, 
the monoclonal antibodies selected in this study recognize 
crystalline cholesterol, specifically a given pattern of 
epitopes present on one or more of the crystal faces. Such 
binding is always measured in competition with binding to 
molecular or BSA-associated cholesterol present in 
solution. Furthermore, none of the antibodies bound to 
cholesterol-BSA conjugates. It could be argued that the 
cholesterol adducts are not exposed to the antibodies when 
BSA is adsorbed to the plate; as the molecule was bound to 
the carrier protein through three different positions, using 
two synthetic procedures and in different reaction 
environments, this seems unlikely, however. We believe 
that the absence of reactivity to noncrystalline forms of 
cholesterol reflects a real feature of the antibodies. It also 
agrees with the reported failure to directly raise antibodies 
against molecular cholesterol [ 181. 
Scanning electron micrographs taken from 
different faces of cholesterol monohydrate 
crystals, immunogold labelled with MAb 
38A1, (I) (001) face, (b) (Ok/) face, (c) 
(101) face and (d) (301) face. 
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Upadhya et al. [19] reported that IgM and IgA isolated 
from the bile of patients that form gallstones accelerate the 
formation of cholesterol crystals. Assuming that nucleation 
is based on antibody-crystal complementarity, as proposed 
by Kam et al. [S], this would suggest the presence in these 
bile secretions of antibodies that recognize the surface of 
cholesterol crystals. The possibility of obtaining specific 
antibodies that recognize groups emerging at the crystal 
surface, but not the component molecule of the crystal, 
was also demonstrated recently for 1,CDNB crystals [17]. 
Interestingly, MAbs reactive with 1,4-DNB crystals were 
produced only after immunization of mice with 1,4-DNB 
crystals, and not after immunization with cholesterol crystals. 
All the MAbs selected for binding to cholesterol and 
1,4-DNB crystals were of the IgM type. This is not sur- 
prising because crystals are most likely to generate a ‘T 
cell independent’ immune response, resulting mainly in 
the production of IgM. In addition, the higher valency of 
the IgM molecule will significantly enhance its binding to 
the almost infinite array of antigens present on the crystal 
surface, by virtue of a cooperative effect. 
Selection of antibodies that specifically recognize choles- 
terol monohydrate crystals was carried out on the basis of 
their ability to bind to the surface of the cholesterol 
monohydrate crystals, but not to other unrelated surfaces. 
Such a procedure is essential since macromolecules tend 
to adsorb nonspecifically onto surfaces. Upon adsorption 
to solid surfaces, proteins are also likely to denature to 
some extent [20,21]. The adsorption may thus be 
partially or totally irreversible. The presence of a 
blocking agent, BSA, at a high concentration, should 
reduce these nonspecific interactions. Even in the 
presence of competitor, we observed that some 
monoclonal antibodies do bind very strongly to all 
surfaces tested [17]. Clone 23C1, chosen as a non- 
selective antibody, was shown by immunofluorescence 
studies to concentrate at crystal imperfections, well 
known to be high energy binding sites. The nonspecific 
adsorption at imperfections may originate from general 
physical-attraction forces, such as may be generated by 
local induction of charges on the surface, or possibly from 
phenomena such as the self-aggregation of the antibody 
on a solid support. 
Immunolabelling of cholesterol monohydrate crystals 
showed lower antibody coverage on the {OOl} face than on 
the {nod and {Olkd faces for all the monoclonal antibodies 
studied. The {OOl} faces are very smooth, whereas the 
{no/) and {Ok/) faces may present more imperfections. 
Labelling at imperfections would, however, result in a 
picture similar to that obtained for 23Cl. We thus do not 
believe that the difference in labelling is due to 
differences in face topography, but rather to differences in 
structural and chemical composition. The (001) face of the 
cholesterol crystal has indeed a character very different 
from the other faces. In aqueous solutions, its surface layer 
is composed of lattice water molecules and of the hydroxyl 
groups of the cholesterol molecule. Lower affinity of 
proteins for surfaces covered by strongly bound lattice 
water molecules was similarly observed by Hanein et al. 
[Z?], using fibronectin as a test protein. 
Among the selected monoclonal antibodies, MAb 58Bl 
displayed the highest degree of specificity for the choles- 
terol crystal surface, compared to all the other solid 
substrates studied. We observed that this antibody 
adsorbs onto the {/lOl) faces of the crystal, rather than onto 
the {ORI) faces. On all the {LO4 faces, the cholesterol 
molecular backbone is exposed in the same orientation. 
Recognition for a given side of the crystal would tend to 
indicate that MAb 58Bl can recognize a repetitive motif 
comprising the part of the cholesterol molecule exposed 
in this direction. We cannot, however, exclude the 
possibility that preferred binding to a defined face of the 
(nOZ) family occurs, but could not be detected under the 
conditions of our experiments. Indeed, with MAb 36A1, 
both immunolabelling techniques indicate a clear 
recognition for a given crystal face, either (301) or (401). 
These two faces are geometrically very close to the (100) 
face, towards which the antibody has a much lower 
affinity. The essential difference between the (301) and 
{ lOO} faces is that the former are stepped faces, thereby 
exposing at the steps both the hydrophobic cholesterol 
backbones and the hydroxyl and water groups, a feature 
which could well be recognized by the antibody, whereas 
{ lOO} faces expose only the cholesterol backbone (Fig. 8). 
At the molecular level the antibody might thus recognize 
a three-dimensional arrangement of molecules. Although 
{lOl} faces exhibit a similar stepped structure, the steps 
might be too close to each other to accommodate the 
bulky IgM molecule. 
To obtain a more precise understanding of the recognition 
of an organized surface by a MAb, two types of studies 
have been initiated. First, by sequencing the antibody and 
modeling its structure in conjunction with the features 
recognized on the crystal faces, we hope to reach a 
molecular understanding of the interactions between the 
antibody and the crystal. We have also undertaken the 
synthesis of self-assembled monolayers exposing chol- 
esterol entities in different orientations and configur- 
ations. The study of antibody recognition of these 
structured surfaces will permit a better definition of the 
surface parameters involved in the recognition process. 
Significance 
We have shown here that monoclonal antibodies 
directed against cholesterol crystal surfaces can be 
selected, and that they exhibit preferential recognition 
of some faces of the crystals relative to others. 
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Fiaure 8 
The cholesterol and water molecules 
exposed at the (301) face and the (100) face 
differ. Packing arrangement of cholesterol 
monohydrate crystals on (a) the (301) face 
and (b) the (100) face. Yellow: cholesterol 
molecule backbone. Red: hydroxyl oxygen 
atoms. Blue: water molecules. The hydroxyl 
groups and water molecules exposed at the 
face are represented in solid, while those 
buried in the layer are represented by 
crosses. 
Antibodies have evolved to be an almost infinitely 
tunable recognition tool for recognizing specific mol- 
ecular structures. The immune system thus provides 
an ideal model for studying molecular recognition in 
biological macromolecules. 
The tine details of the molecular interactions between 
antibodies and antigens are difficult to define system- 
atically, however, because antigen structures vary 
over a wide range and are themselves not syste- 
matically defined. In contrast, crystal surfaces are 
homogeneous, repetitive, and present a controlled 
variability of structures that are atomically defined 
and whose organizations are known. A complete 
characterization of antibodies that recognize ordered 
structures such as crystals, and of their complexes 
with the specific selected faces, may thus assist in the 
understanding of antibody-antigen interactions in 
general. A detailed understanding of this kind may 
also provide insight into the immune response to 
extraneous solid surfaces inside the organism, which 
occur, for example, when crystalline structures form 
as part of the pathology of a disease or when foreign 
substances are surgically implanted. 
Materials and methods 
Materials 
Cholesterol (99 %J pure), cholesteryl hemisuccinate, 5-cholenic acid-38 
01, 5-cholesten-38ol-7-one, p-nitrophenyl phosphate and bovine serum 
albumin 098 o/o pure) were purchased from Sigma Chemical Co. (St. 
Louis, Missouri). Dimethylaminopropyl-N’-ethylcarbodiimidhydrochloride 
was purchased from Merck (Germany). C-carboxymethylamine hemi- 
hydrochloride was purchased from Aldrich (Milwaukee, WI). 1,4-Dinitro- 
benzene was purchased from Fluka (Switzerland). The antigen-binding 
fragments (F(ab),) of a goat-anti-mouse antibody, conjugated to alkaline 
phosphatase, rabbit-anti-mouse IgM and goat-anti-mouse F(ab)a, 
rhodamine conjugated, were all obtained from Jackson lmmunoresearch 
(West Grove, PA). Goat-anti-mouse IgG + IgM, conjugated with 30 nm 
colloidal gold was obtained from Bio-Cell (Cardiff, UK). Antibody 2C5-6 
was obtained from the American Type Culture Collection (access 
number HB 8995). SpectraIpor molecular porous membrane tubing was 
purchased from Spectrum Medical Industries, Inc. (Los Angeles, CA). 
Microtiter polystyrene plates were purchased from Nunclon (Denmark). 
Cholesterol crystals were grown on 13 mm microscope glass cover slips 
manufactured by Chance Propper Ltd. (Smethwick, Warley, England). 
Differential scanning calorimetry was performed with a Mettler TCl TA 
processor. Scanning electron microscopy was performed with a Jeol 
JMS 6400. A Molecular Devices microplate reader was used for ELISA. 
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Growth of crystals 
Choierterol monohydrate war, oryetallizsd by heating 0.3 Q ohoierterol 
in 60 ml acetone to boiling, while etirrlng. Twenty ml of doubl~dirtllird 
water (DDW) were then added, and the eoiution war boiled for 30 a, 
Cooling to room temperature induoer formation of a white cloudy 
suepenelon after a few hour& The rolutlon wae then rhaken vigorouely, 
and allowed to oryetallizs overnight. The oryetalr were flitsnd and wed 
for ELISA exprrimente. The filtrate waa further divided into l&ml 
allquote in 25ml brakerr, oontainlng a oover gla8e elide, The oryatala 
attached to the glaer oover ellder wore uerd for immunolabrlllng 
exprrimrnte. The ory8taiiine phaaee obtained were oheokrd by 
differential roanning calorimetry 1161 and the oryrtale examined under 
an optioal mioroaoope in white and oroaa.polarized light, Batohra of 
oryatala with a high level of imperfeotiona ware dleoardrd, 1,4*DNB 
and 1,3mDNB oryatala were grown aa deaorlbsd 1171, 
Production of monoclonal antibodies 
MAb 36Al originated from a Balblo mouse immunized with oholerterol 
monohydratr oryalaia by aurgic-al implantation of the oryetala In the aplrm 
(twice at threeweek intervala) followed by one lntraperitoneal Injection, 
MAb 23Cl I MAb 66Bl and MAb 12281 were produced aa deaoribed 
[171, Screening waa performed by ELISA on oholraterol and 1,4-DNB 
oryatala In parallel, leotyping wae oarried out uaing the mouse mon*AB 
Kit (HRP), Aaoltea were produosd aa deaorlbed [231, 
ELBA of antibody binding to crystals 
For each aample, oholeaterol monohydrate oryrtala (1.6 mg) were 
piaoed in a BSA.preooated eppsndorf tube, Preooatlng wae performed 
by incubation with 0.6 % BSA in phoaphatebuffered aallne (PBS), 1 h, 
followed by waahing three timer with PBS. All wrahinga and 
aeparationa were performed after aplnning down the oryatala by a ahort 
oentrifugation, 200 ~1 of aerum or hybridoma aamplea, aequentlally 
diluted in binding buffer (PBS, 05 96 BSA, 0,02 96 NaN, aaturatad with 
oholeaterol) were added, saoh dilution In duplloata, After inoubation for 
1 h at room temperature with gentle agitation, tha oryatalr were waahed 
twice with PBS saturated wlth oholeeteroi. The oryatala were then 
incubated for 46 min with 200 ~1 l lkalina~phoephataee-oonjugated 
goat.anti.mouaa F(ab)‘*, diluted 1 /l 000 in binding buffer, waahad aa 
previoualy, and incubated with 200 ~1 of aubatrate buffer (1 mg ml-1 of 
pnitrophenylphoaphate in 10 % diethanolamino buffer, O-01 96 MgCi,, 
0.02 % NaN,) for 30 min, until the color developed, The reaction waa 
atopped by addition of 60 ~1 0.4 M EDTA, the eppendorf orntrifuged, 
and the aolutiona tranafarred to miorotiter plater. Abaorption waa 
determined at 402 nm. The aama prooedure waa applied in parallel to 
BSA.ooated eppendorf tuber without oryatala, and the abaorbanoe of 
the aoiution from tha eppandorf without the oryatala waa aubtraotad 
from that of the aamplaa, 
For hybridoma aoreening the hybridoma medium, diluted l/l 0, waa 
inoubated with the oryatala in PBS saturated with ohole#terol, After 
waahlng twioe with PBS, 0.6 % BSA, 0.02 % NaN,, the reaotion waa 
continued aa daaoribed previously, 
ELIBA on 1,4*DNB cryataia waa performed In a aimilar manner, with 
the following modificationa: i) 2 mg of oryataia ware used for eaoh 
aampie; Ii) all the inoubation and waehing aolutiona were saturated with 
1,4mDNS; iii) the oryataia were tranaferrad to a new BSA.ooated 
eppendorf before adding the enzyme aubatrate, and the ooior waa 
allowed to develop for 60 min. 
Adsorption of monoclonal antibodies to polystyrene 
The hybridoma culture medium wae arrlaliy diluted In PBS, and adaorbed 
onto miorotltar platea for 1 h, at room temperature. The piatea were wzehed 
twioe for 10 min arch, with PBS/BSA, and blocked by inoubatlon with 
PBS/BSA for 1 h, The weila were incubated for 46 min with goat.antl~rabbit 
F(ab),, and waehed three tlmea for 6 min arch wlth PBS, 1 % BSA. Color 
development waa performed ae deeoribed above wlth a 2-h Incubation. 
Cholesterol coeting of polystyrene plates 
Choierterol waa coated onto the aurfaoe of U.bottom wella, in 
microtiter plater, by addition of an ethanolio rolution oontaining 1 or 10 
FQ ohoieaterol per well. Aa a oontrol pure ethanol waa added. The 
plate waa dried and atorad ae deaoribed 1161, Blocking and reaotion 
with monoclonal antibodiea were carried out aa deaoribed above. 
Blooklng and reaotion with aaoitea waa performed ae deaorlbed [la], 
Synthesis of 6~cholesten-S~~o/-7~@-carboxymethyl)oxime 
6Gholeaten~3@-ol~7~one (26 me) waa dlaaolved in ethanol (6 ml), and 
a solution of C-oarboxymethyiamine hem/hydrochloride (17 me) in 2N 
KOH (0,6 ml) waa added, The mixture waa refluxed for 3 h, cooled and 
oonoentrated by evaporation, Water (3 ml) waa added, the mixture waa 
extraoted with ethylacetate (2 x 10 ml), and the product waa purified by 
flaah chromatography (7:3 ether:ethylaoetate). lH NMR (Bruker 400 
Mhz, CDCI,) 6 0.7 (C-16 CH,), 0.66 (C-26, CH3), 0,66 (C-27, CH,), 
0.93 (C-21, CH,), 1 .l (C-1 0 CHz), 1.2-2-6 (ateroid backbone, 24H), 
3.7 (C-3, H), 4,7 (0-CHz-), 6,6 (C-4 H anf& 6.2 (C-4 H ayn), 
Conjugation of Steroid8 to BSA 
Choleateryl hemiauooinate, 6.cholenic aoid.3p.ol and 6~aholeaten.BP* 
oi-7~(O~oarboxymethyi)oxime were oonjugated to BSA by activation of 
the oarboxyllo group uaing the following general procedure, Each 
steroid waa dlaaolved in 1 ml well.drled dloxane (3 x 10-O mole), 1 .l 
equivalent of 1,3.dioyciohexyoarbodiimlde and l-1 equivalent of 
N.hydroxyauooinimida were added, and tha aolution waa atirred for 24 
h. The aolutlon waa filtered through a Pasteur pipette equipped with a 
ootton plug, and the reauiting filtrate waa oombinad with 0.016 
equivalent BSA (diaaolved in 2 ml PBS) and atirred overnight, The 
protein aolutlon waa placed in a calluloae dlalyaia membrane 
(SPECTRAIPOR 6-6000 mw) and dialyzed againat PBS (3 I) with five 
changer, The reaultlng dialyaate waa diluted with PBS, centrifuged 
and flltered through a 0,P y,m filter, 
Alternatively, BSA oonjugatea were prepared by direct attachment via 
N-(3~dimethylaminopropyl)~N’~ethyloarbodilmldhydrochlorida (EDC), A 
aoiution of BSA (20 mg), aterold (6 mg) and EDC (3 mg) wae prepared In 
10:1 DDW:pyridlne. The mixture waa atirred overnight. The protein 
aoiutlon wan placed in a oeiluioae dialyela membrane and dlalyzad againat 
DDW (3 I) with three ohangea, The resulting dialyrate waa diluted wlth 
deionized water, oentrifuged and flltared through a 0.2 km filter, 
Characterization of the BSA-steroid conjugate8 
The BSA-ateroid conjugataa ware characterized by hydrolyaia of tha 
ateroida and maaaurement of their oonoentration by NMR. Eaoh 
BSA-ataroid aample (4 ml) waa lyophilizad, ethanol (6 ml) and KOH 
(300 ~1, 33 ‘XI v/v) were added, and the aolution atlrred for 24 h at 
36 “C, The hydrolyzed aoiution waa extracted with water (10 ml) and 
chloroform (10 ml), the organio layer waa aaparated and evaporated to 
dryneae. The amount of ataroid waa quantified by NMR rpectroaoopy 
using dioxane aa an internal atandard and comparing the intenaity of 
the methyl peaka to that of the standard, 
Binding of the monoclonal antibodies to protein conjugate8 
Protein oonjugatea were diluted 1 /l 0 and ooated onto 06well microtiter 
platea, by addition of 100 pi of protein aolution to each well. The plate 
waa lnoubated for 2 h, warhed twice wlth PBS and kept overnight at 
4 “C. The wella were biooked by incubation with 0.26 46 gelatin in PBS 
for 30 min, followed by two wazhea with PBS. Antibody aaoitaa (36A1, 
6681, 12281 and 2C6.6), diluted 1 H 0 in 0.26 46 gelatin in PBS, were 
incubated for 1 h, at room temperature, The plater were waehed three 
timea for 6 min each with PBS, incubated with goat.anti.mouae F(ab), 
aaoondary antibody and again waehed three timer for 6 min each wlth 
PBS. Color development waa performed aa deacrlbed above. 
lmmunofluorescenoe and immunogold labelling experiment8 
Choiaaterol monohydrate oryztaia, grown attached to glarr Cover 
aiidea (1.3 cm), ware plaaed in 24.well polystyrene diahea praooated 
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with BSA. The crystals were incubated 1 h with hybridoma media 
diluted 1120 in binding buffer, at room temperature, with elow agitation, 
They were waahed three times for 6 min each with washing buffer, and 
incubated 1 h with rhodamine-labelled goat-anti-mouse F(ab)* antibody 
diluted l/l 00, or 30 min with 30 nm colloidal gold-conjugated goat- 
anti-mouse IgG + IgM antibody, diluted 1160, The crystals were 
washed again with washing buffer a8 above, and very briefly with 
DDW, The fluoreecently labelled cry&ale were transferred to micro- 
scope slides, air dried and observed under fluorescent light with an 
optical microscope. The cover elidee with the gold-labelled crystals 
were air dried, frozen in liquid nitrogen, lyophilized overnight, sputter- 
coated with gold, and examined in the acanning electron microscope 
at 16 kV by secondary electron emiaeion. Lyophilization of cholesterol 
monohydrate crystals prevents damage, because it prevents lattice 
water from being extracted from the cry&ale by the electron beam or 
by the sputtering process. However the lyophilized samples are only 
stable for up to 72 h. Beyond this time period the cryetals presumably 
undergo a phase transition and disintegrate. 
Cholesterol monohydrate crystals grown under the conditions of our 
experiment expressed well developed (ho/I and (Ok/) faces. The Miller 
indexes of the faces were determined by accurately measuring the 
dihedral angle between these faces and the easily identifiable (001) 
plane of the crystals, from electron miorographs taken with the faces 
exactly edge-on to the plane of the picture. This identifies 
unambiguously whether the crystal is being examined down a*, ((/IO/) 
faces) or down b’, ((Ok/) faces). To identify the faces viewed face-on to 
the picture, the crystals were tilted up to 80°, and the angle between 
the (001) plane and the faces examined was aeaeeeed, aa close a8 
possible to an edge-on position. Once the facee were identified, the 
gold beads were counted in at leaat three different locations on each 
face, at magnification 20 000x. Only samples where the diatribution 
and the number of gold beads could be unambiguously established 
were taken into account. 
Labelling of cholesterol crystals with dansylated BSA 
Labelling of BSA with danayl chloride wae performed by mixing 200 p,l 
of a aolution of 2.6 mg danryl chloride per ml acetone with 200 pl of 
0.2 M NaCO,, pH 8.6, containing 6 mg BSA. The mixture was stirred 
2 h at room temperature, and dialyzed three timea against 600 ml PBS. 
Cholesterol monohydrate crystals were incubated 2 h in PBS eatu- 
rated with cholesterol, containing 0.01 46 dansyl-BSA, with or without 
06 96 unlabelled SSA, The cryatals were then washed three times with 
PBS saturated with cholesterol, and examined under fluoreecent light 
with an optical microscope. 
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